{
    "nctId": "NCT00100750",
    "briefTitle": "Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Gemcitabine and R115777 Combination Therapy for Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Carcinoma, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Objective response rate (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed breast cancer and clinical evidence of metastatic disease\n* Patients may have received any number or type of hormonal therapies, either for stage IV disease and/or as adjuvant therapy; patients may have received trastuzumab therapy\n* Patients may have received up to 2 prior chemotherapy regimens as therapy for metastatic breast cancer; patients must have recovered from the myelosuppressive effects of prior chemotherapy and all toxicity must have recovered to grade less than or equal to 1\n* Concomitant bisphosphonates are allowed for patients with bone metastases\n* Localized radiotherapy that does not influence the single evaluable lesion is allowed prior to the initiation of therapy; patients must have recovered from the myelosuppressive effects of previous radiotherapy (at least 4 weeks)\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\> 20 mm with conventional techniques or as \\> 10 mm with spiral computed tomography (CT) scan\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 (Karnofsky \\> 60%)\n* Leukocytes \\>= 3,000/mcL\n* Absolute neutrophil count \\>= 1,500/mcL\n* Platelets \\>= 100,000/mcL\n* Total bilirubin within normal institutional limits\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.5 \u00d7 institutional upper limit of normal\n* Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n* There should be a four-week delay between the conclusion of radiation and the start of gemcitabine, provided the acute effects of radiation treatment have resolved\n\nExclusion Criteria:\n\n* Prior therapy with farnesyltransferase inhibitor or gemcitabine for metastatic breast cancer\n* Patients with leptomeningeal disease and/or brain metastasis\n* Patients with symptomatic lymphangitic pulmonary metastases\n* Patients with peripheral neuropathy greater than or equal to grade 2\n* No history of concomitant malignancy except for non-melanoma skin cancer or cervical cancer in situ or other malignancy treated curatively and no evidence of disease for at least five years\n* Patients who have had chemotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Patients may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib (R115777), or imidazole derivatives\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}